Cargando…
A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil(®))
Human papillomaviruses (HPVs) are one of the most common sexually transmitted infections and remains a public health problem worldwide. There is strong evidence that HPV causes cervical, vulva and vaginal cancers, genital warts and recurrent respiratory papillomatosis. The current treatments for HPV...
Autor principal: | Govan, Vandana A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503667/ https://www.ncbi.nlm.nih.gov/pubmed/18728721 |
Ejemplares similares
-
Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
por: Halfon, Philippe, et al.
Publicado: (2010) -
Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine
por: Diaz, Maria Lina
Publicado: (2010) -
A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model
por: Yin, Fei, et al.
Publicado: (2017) -
Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males: Profile Report
por: Garnock-Jones, Karly P., et al.
Publicado: (2012) -
Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
por: Zurek Munk-Madsen, Maria, et al.
Publicado: (2017)